S. Laighold

Clinical Study Early Real-World Experience with CoreValve Evolut PRO and R Systems for Transcatheter Aortic Valve Replacement

C. Grines, G. Rao, Shikha Sheth, 2019 .

Early Real-World Experience with CoreValve Evolut PRO and R Systems for Transcatheter Aortic Valve Replacement

C. Grines, G. Rao, Shikha Sheth, 2019, Journal of interventional cardiology.

Initial clinical experience with a selective A2A receptor agonist, regadenoson, in a patient with end-stage renal disease on hemodialysis

R. Druz, S. Laighold, 2009, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

Color Paucity as a Marker of Transcatheter Valve Thrombosis.

L. Gillam, S. Laighold, K. Koulogiannis, 2017, JACC. Cardiovascular imaging.

A post-partum woman with dyspnea

S. Laighold, 2005 .

A novel diagnostic approach to a mass on a device lead

L. Epstein, A. K. Williamson, S. Laighold, 2019, HeartRhythm case reports.

Self-expanding Transcatheter vs Surgical Aortic Valve Replacement in Intermediate-Risk Patients: 5-Year Outcomes of the SURTAVI Randomized Clinical Trial.

Sara K. Rostanski, P. Teirstein, J. Bavaria, 2022, JAMA cardiology.